A
Amphivena Therapeutics
Treatments to address hematologic malignancies
About Amphivena Therapeutics
Amphivena Therapeutics is a biotechnology company that operates in the healthcare sector, specifically in the field of immuno-oncology. The company's primary focus is on the development of innovative therapies to treat hematologic malignancies, which are cancers that affect the blood, bone marrow, and lymph nodes.
Amphivena's business model revolves around the research, development, and commercialization of novel therapeutics. The company's primary clients are patients suffering from hematologic malignancies, and it operates in the global pharmaceutical market. The company generates revenue through the development and sale of its therapeutic products.
Amphivena's flagship product, AMV564, is a T cell engager that is currently in clinical trials. This product is designed to engage the patient's immune system to destroy cancer cells, offering a potential new treatment option for patients with hematologic malignancies.
In summary, Amphivena Therapeutics is a biotech company that develops innovative therapies for the treatment of hematologic malignancies. The company operates in the global pharmaceutical market, serving patients suffering from these types of cancers. Its revenue is generated through the development and sale of its therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- San Francisco, United States
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Sep 2019 | $62M | $248M | Aju IB Investment · NAWTON TOWER ESTATES LIMITED · Qiming Venture Partners · +ND Capital | ↗ |
| LATE VCOther financing | Dec 2018 | $39M | $155M | Undisclosed | — |
Growth signals
Latest recorded traffic for Amphivena Therapeutics is 220 monthly website visits, down 97.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Repron TherapeuticsEpigenetic silencing platform for tumor recurrence repression |
Milan, Italy | Operational | 1 | $2.2M | $8.8M |
 PrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy |
Jette, Belgium | Operational | |||
 RayzeBioDefeating cancer with radiopharmaceutical medicines |
San Diego, United States | Acquired | |||
 CellmAbsCellmabs is focused on researching and developing innovative biopharmaceuticals for the treatment of cancer |
Óbidos, Portugal | Acquired | |||
 ADCendoA Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers |
Copenhagen, Denmark | Operational | |||
 Mediphage BioceuticalsCures for chronic diseases |
Toronto, Canada | Operational | |||
 AutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases |
London, United Kingdom | Operational | |||
 SerenexDrug discovery and development company that is focused on oncology |
Durham, United States | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- CBCentocor Ortho Biotech
Series B and later8 investors entered at this stage
Qiming Venture Partners
+ND Capital
Aju IB Investment- NLNAWTON TOWER ESTATES LIMITED
MPM BioImpact
Clough Capital Partners- KCKaitai Capital
Industrial Investors Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amphivena Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amphivena Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.